免疫与基质浸润对肌层浸润性膀胱癌保留膀胱三联治疗预后的影响
本研究利用临床级平台对136例接受保留膀胱三联治疗(TMT)的肌层浸润性膀胱癌(MIBC)患者原发肿瘤进行转录组基因表达谱分析,并分析另223例接受新辅助化疗(NAC)联合根治性膀胱切除术(RC)患者的表达数据。结果显示T细胞活化和干扰素γ信号特征与TMT队列疾病特异性生存(DSS)改善相关(T细胞HR 0.30 [0.14-0.65],p=0.002),而基质特征与NAC+RC队列DSS较差相关(p=0.006)。
要点
- TMT队列中T细胞活化特征与DSS改善相关(HR 0.30 [0.14-0.65],p=0.002)。
- NAC+RC队列中基质特征与DSS较差相关(p=0.006),TMT队列中无此关联。
- 基因表达谱有潜力指导膀胱癌治疗决策,需进一步研究验证。
核心结论
- MIBC中较高的免疫浸润与TMT后DSS改善相关,而较高的基质浸润与NAC+RC后DSS较短相关。
研究设计与样本
- 对单中心136例接受TMT的MIBC患者原发肿瘤进行转录组基因表达谱分析,5年观察到60例总生存事件,无事件患者中位随访5.0年(四分位距3.1,5.0)。
- 另分析223例接受NAC+RC的MIBC患者表达数据。
主要发现
- TMT病例基因表达谱鉴定出管腔型(N=40)、管腔浸润型(N=26)、基底型(N=54)和claudin-low型(N=16)亚型。
- TMT队列中T细胞活化和干扰素γ信号特征与DSS改善相关(T细胞HR 0.30 [0.14-0.65],p=0.002),NAC+RC队列中无此关联。
- NAC+RC队列中基质特征与DSS较差相关(p=0.006),TMT队列中无此关联。
局限性
- 本研究受其回顾性性质限制。
- 应开展更多研究以确定基因表达谱能否预测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bladder-sparing trimodality therapy (TMT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection are needed. OBJECTIVE: To evaluate the prognostic value of immune and stromal signatures in MIBC treated with TMT. DESIGN, SETTING, AND PARTICIPANTS: We used a clinical-grade platform to perform transcriptome-wide gene expression profiling of primary tumors from 136 MIBC patients treated with TMT at a single institution. We observed 60 overall survival events at 5yr, and median follow-up time for patients without an event was 5.0yr (interquartile range 3.1, 5.0). Expression data from another cohort of 223 MIBC patients treated with neoadjuvant chemotherapy (NAC) and RC were also analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular subtype, immune, and stromal signatures were evaluated for associations with disease-specific survival (DSS) and overall survival (OS) in TMT patients, and in patients treated with NAC and RC. RESULTS AND LIMITATIONS: Gene expression profiling of TMT cases identified luminal (N=40), luminal-infiltrated (N=26), basal (N=54), and claudin-low (N=16) subtypes. Signatures of T-cell activation and interferon gamma signaling were associated with improved DSS in the TMT cohort (hazard ratio 0.30 [0.14-0.65], p=0.002 for T cells), but not in the NAC and RC cohort. Conversely, a stromal signature was associated with worse DSS in the NAC and RC cohort (p=0.006), but not in the TMT cohort. This study is limited by its retrospective nature. CONCLUSIONS: Higher immune infiltration in MIBC is associated with improved DSS after TMT, whereas higher stromal infiltration is associated with shorter DSS after NAC and RC. Additional studies should be conducted to determine whether gene expression profiling can predict treatment response. PATIENT SUMMARY: We used gene expression profiling to study the association between tumor microenvironment and outcomes following bladder preservation therapy for invasive bladder cancer. We found that outcomes varied with immune and stromal signatures within the tumor. We conclude that gene expression profiling has potential to guide treatment decisions in bladder cancer.
引用
- Efstathiou JA, Mouw KW, Gibb EA, et al. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol. 2019. PMID: 30712971. doi:10.1016/j.eururo.2019.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。